Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective

被引：16

作者：

Houda, Ilias ^{[1
]}

Dickhoff, Chris ^{[2
]}

Uyl-de Groot, Carin A. ^{[3
]}

Damhuis, Ronald A. M. ^{[4
]}

Reguart, Noemi ^{[5
]}

Provencio, Mariano ^{[6
]}

Levy, Antonin ^{[7
]}

Dziadziuszko, Rafal ^{[8
]}

Pompili, Cecilia ^{[9
]}

Di Maio, Massimo ^{[10
]}

Thomas, Michael ^{[11
,12
,13
]}

Brunelli, Alessandro ^{[14
]}

Popat, Sanjay ^{[15
]}

Senan, Suresh ^{[16
]}

Bahce, Idris ^{[1
]}

机构：

[1] Amsterdam UMC, Locat VU Med Ctr, Canc Ctr Amsterdam, Dept Pulm Med, Boelelaan 1117, NL-1081HV Amsterdam, Netherlands

[2] Amsterdam UMC, Locat VU Med Ctr, Canc Ctr Amsterdam, Dept Cardiothorac Surg, Boelelaan 1117, NL-1081HV Amsterdam, Netherlands

[3] Erasmus Univ, Inst Med Technol Assessment, Erasmus Sch Hlth Policy & Management, POB 1738, NL-3000 DR Rotterdam, Netherlands

[4] Netherlands Comprehens Canc Org, Dept Res, Godebaldkwartier 419, NL-3511 DT Utrecht, Netherlands

[5] Hosp Clin Barcelona, Dept Med Oncol, C Villarroel 170, Barcelona 08036, Spain

[6] Hosp Univ Puerta Hierro, Dept Med Oncol, C Joaquin Rodrigo 1, Majadahonda 28222, Madrid, Spain

[7] Univ Paris Saclay, Int Ctr Thorac Canc CICT, Dept Radiat Oncol, Gustave Roussy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France

[8] Med Univ Gdansk, Fac Med, Dept Oncol & Radiotherapy, PL-80210 Gdansk, Poland

[9] Univ & Hosp Trust Osped Borgo Trento, Dept Thorac Surg, Ple A Stefani 1, I-37126 Verona, Italy

[10] Univ Turin, Dept Oncol, Med Oncol 1U, AOU Citta Salute & Sci Torino, I-10126 Turin, Italy

[11] Heidelberg Univ Hosp, Dept Thorac Oncol, Thoraxklin, Neuenheimer Feld 672, D-69120 Heidelberg, Germany

[12] Partnership DKFZ & Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, NCT Heidelberg, Neuenheimer Feld 672, D-69120 Heidelberg, Germany

[13] Translat Lung Res Ctr Heidelberg TLRC H, German Ctr Lung Res, Heidelberg, Germany

[14] St James Univ Hosp, Dept Thorac Surg, Beckett St, Leeds LS9 7TF, England

[15] Royal Marsden NHS Fdn Trust, Lung Unit, Fulham Rd, London SW3 6JJ, England

[16] Amsterdam UMC, Locat VU Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Boelelaan 1117, NL-1081HV Amsterdam, Netherlands

来源：

LANCET REGIONAL HEALTH-EUROPE | 2024年 / 38卷

关键词：

Lung neoplasms; Immune checkpoint inhibitors; Protein kinase inhibitors; Disease-free survival; Humans; Europe; United States; United States Food and Drug Administration; Access primary care; Adjuvant chemotherapy; Biomarkers; Surgery; PHASE-III; PLUS CHEMOTHERAPY; ADJUVANT-CISPLATIN; SURGERY; SURVIVAL; NSCLC; RECOMMENDATIONS; PEMBROLIZUMAB; RESECTION; PLACEBO;

D O I：

10.1016/j.lanepe.2024.100841

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.

引用

页数：8

共 50 条

[31] The role of induction therapy for resectable non-small cell lung cancer
Stinchcombe, Thomas E.
Socinski, Mark A.
DRUGS, 2007, 67 (03) : 321 - 332
[32] Molecular prognostic factors in resectable non-small cell lung cancer
Vielh, P
Spano, JP
Grenier, J
Le Chevalier, I
Soria, JC
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (03) : 193 - 197
[33] The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne, Elizabeth G.
Fick, Cameron N.
Isbell, James M.
Chaft, Jamie E.
Altorki, Nasser
Park, Bernard J.
Spicer, Jonathan
Forde, Patrick M.
Gomez, Daniel
Iyengar, Puneeth
Harpole Jr, David H.
Stinchcombe, Thomas E.
Liberman, Moishe
Bott, Matthew J.
Adusumilli, Prasad S.
Huang, James
Rocco, Gaetano
Jones, David R.
ANNALS OF THORACIC SURGERY, 2024, 118 (01): : 119 - 129
[34] Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Drosslerova, M.
Sterclova, M.
Vasakova, M.
Taskova, A.
Hytych, V.
Horazd'ovsky, P.
Richterova, E.
Smetakova, M.
Havel, L.
ANNALS OF ONCOLOGY, 2019, 30
[35] Treatment of resectable stage IIIA non-small cell lung cancer
Cardenal, Felipe
Palmero, Ramon
JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15
[36] Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
Gutierrez-Sainz, Laura
Cruz-Castellanos, Patricia
Higuera, Oliver
De Castro-Carpeno, Javier
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (10)
[37] The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer
Thomas E. Stinchcombe
Mark A. Socinski
Drugs, 2007, 67 : 321 - 332
[38] Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review
West, Howard
Kim, Jae Y.
JAMA ONCOLOGY, 2024, 10 (02) : 249 - 255
[39] Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
Gwon, H. R.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S520 - S521
[40] Multimodality therapy in surgically resectable early non-small cell lung cancer
Goldberg, M
IN VIVO, 2000, 14 (01): : 51 - 60

← 1 2 3 4 5 →